May 27, 2021
Candel Therapeutics to present at upcoming Jefferies Virtual Healthcare Conference
NEEDHAM, Mass.– Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, M.D. Ph.D., President and Chief Executive Officer, will present an overview of the Company at the upcoming Jefferies
Additional Formats
May 11, 2021
Candel Therapeutics names Carrie S. Cox as Chairman of its Board of Directors
NEEDHAM, Mass.– Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Carrie S. Cox has been named Chairman of the Board of Directors, effective immediately. Paul Manning, the outgoing Chairman, will
Additional Formats
Apr 13, 2021
Candel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.
NEEDHAM, Mass.– Candel Therapeutics, a clinical-stage biotechnology company, developing novel immune-based cancer therapeutics, today announced the initial formation of its Research Advisory Board (RAB) with the appointment of James Allison, Ph.D. (MD Anderson Cancer Center), Henry Brem, M.D.
Additional Formats
Displaying 11 - 16 of 16